Default company panoramic image

Vapogenix, Inc

Vapogenix is creating a new category of analgesics to treat localized pain without the systemic side effects of existing drugs.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Houston, TX, USA
  • Currency USD
  • Employees 6
  • Website

Company Summary

Vapogenix's technology is based on the novel finding that volatile anesthetics, when formulated, show a reversible localized analgesic effect. Our first product is a quick acting topical analgesic that is substantially faster than competing products and will be used prior to venous access and minor dermatological procedures. Successful development of this product will enable the development of a new class of analgesics to treat localized pain.


  • Default avatar
    Heather Giles
    Chief Scientific Officer

    Dr. Giles is an experienced pharmaceutical executive with over 20+ years of drug development experienced, as global strategy director of asthma at GSK, global director pharmacology at Glaxo Welcome and VP, Drug Development, Encysive Pharmaceuticals. PhD Pharmacology, University of London

  • Default avatar
    Terry Farmer
    Director, CMC and Analytical Services

    Dr. Farmer has substantial industry experience directing CMC activities and overseeing GMP manufacture of pharmaceuticals.Dr. Farmer was previously Director of Analytical Services at Encysive, where she led the teams responsible for analytical and bioanalytical chemistry from drug discovery through to the market. Ph.D. in Biochemistry from the UT-Health Science Center in Houston and a B.S. in Chemistry from the University of Tulsa.

  • Default avatar
    Clarice Motter

    Ms. Motter has 25+ years of experience in both public and privately held companies. She earned her MBA from the UCLA Anderson School of Management and worked as an Auditor with KPMG prior to entering the private sector working in life sciences. Ms. Motter has been involved with companies in all stages of development. She has been the CFO for many life science companies including: LifeCell, Repros, Chrysalis, Aronex, and RGene.

  • Default avatar
    Danguole Altman
    President and CEO

    Danguole Altman is an experienced health care CEO. Ex-CEO FemPartners, a successful women's health care services company she founded and raised $15M+ to capitalize. Ex- McKinsey consultant, HCA. AB Economics Harvard, MBA Yale


  • Default avatar
    Michael Blaney, Blaney Law (general) and Kathryn Doyle (IP)
    Default avatar
    Clarice Motter, CFO. Outside tax accountant: PKF Texas

Previous Investors

  • Default avatar
    Aragain Capital